Introduction

AviClear is the first and only FDA-cleared laser system specifically designed to treat the root cause of acne by selectively targeting and destroying sebaceous glands. Manufactured by Cutera, this innovative 1726nm laser received FDA clearance in 2022 for the treatment of mild, moderate, and severe inflammatory acne vulgaris. Unlike traditional acne medications that manage symptoms, AviClear offers a potential long-term solution by reducing sebaceous gland activity without systemic side effects associated with oral medications.

Device Technology and Mechanism

AviClear utilizes a 1726nm infrared laser wavelength specifically selected for its unique optical properties. This wavelength was chosen through careful spectroscopy analysis demonstrating selective absorption by sebaceous gland lipids (sebum) while sparing surrounding tissue structures. The laser operates at 1726nm, a wavelength that penetrates to sebaceous gland depth (approximately 2-3mm) without significant absorption by water or other chromophores in the epidermis and upper dermis.

The device employs selective photothermolysis principles, generating precise thermal injury to sebaceous glands while preserving the follicular epithelium, epidermis, and surrounding dermis. A contact-cooling sapphire window cools the skin surface during energy delivery, preventing epidermal damage while focusing thermal energy on the sebaceous gland target.

Histological analysis following treatment demonstrates total necrosis of sebaceous glands with complete sparing of the epidermis and follicular epithelium. This selective destruction of sebocytes reduces sebaceous gland function and sebum production, addressing the primary pathogenic factor in acne development. The therapeutic mechanism targets one of the four cardinal factors in acne pathogenesis (Propionibacterium acnes colonization, follicular hyperkeratinization, sebum production, and inflammation), distinguishing it from topical and oral medications that address other pathways.

Clinical Efficacy Data

AviClear's efficacy is supported by robust clinical trial data. The pivotal US multicenter study enrolled 104 patients with moderate-to-severe facial acne across Fitzpatrick skin types II-VI. Treatment consisted of three 30-minute sessions spaced 4 weeks apart.

Primary Efficacy Endpoint (26-week post-treatment): 87.3% of patients achieved at least a 50% reduction in inflammatory lesion count. Additionally, 41.8% of patients were graded as "clear" or "almost clear" by blinded investigator assessment using the Investigator Global Assessment (IGA) scale.

Inflammatory Lesion Response: At 4 weeks post-final treatment, 32.6% of patients achieved ≥50% reduction in inflammatory lesions, demonstrating progressive improvement with delayed measurement timepoints. By 26 weeks post-treatment, this improved to 87.3%.

IGA (Investigator Global Assessment) Scores at 26 Weeks:

  • IGA 0-1 (clear/almost clear): 41.8%
  • IGA 0-2 (clear/almost clear/mild): 66.3%
  • IGA 0-3 (clear/almost clear/mild/moderate): 87.3% (≥50% lesion reduction)

One-Year Durability Data: At 52 weeks post-treatment, clinical improvement continued and stabilized. The percentage of patients achieving IGA 0 or 1 (clear or almost clear) increased from 35.9% at 12 weeks to 66.2% at 52 weeks, demonstrating progressive improvement over the full year post-treatment.

Long-Term Efficacy (24 months): International studies with 24-month follow-up data demonstrated sustained acne clearance in approximately 88% of treated patients, with a 97% reduction in inflammatory lesions at the two-year timepoint. These results confirm durable long-term benefits rather than temporary improvement.

Efficacy Across Skin Types: Clinical trial results were consistent across Fitzpatrick skin types II-VI, demonstrating equivalent efficacy in diverse patient populations. No significant differences in clearance rates or adverse event profiles were observed based on baseline skin phototype.

Treatment Protocol

Treatment Schedule: Three treatment sessions are spaced 4 weeks apart. Each session lasts approximately 30 minutes. No anesthesia is required, and most patients experience minimal discomfort during treatment.

Treatment Parameters: The device operates at a fluence of approximately 20.5 J/cm² with a 3mm spot size. Contact cooling occurs throughout energy delivery, minimizing epidermal discomfort and preventing thermal damage to non-target structures.

Treatment Area: The entire face is typically treated, including the forehead, cheeks, chin, and nose. Some practitioners may treat the neck, chest, and back if acne is present in these areas.

Patient Experience and Side Effects

Pain and Discomfort: No pain mitigation (topical anesthetic or cooling) was required by any patient in the pivotal clinical trial, and most patients tolerate treatment without significant discomfort. Some patients describe a warm sensation or mild stinging, though serious discomfort is rare.

Immediate Post-Treatment (0-24 hours): Most patients experience mild erythema (redness) that typically clears within a few hours to one day. Mild edema (swelling) may develop and usually resolves within 24-48 hours. Patients can immediately resume normal activities and return to work or school.

Common Temporary Side Effects:

  • Transient erythema and mild edema resolving within 1-3 days
  • Post-treatment acne purging or flaring approximately 1 week after treatment, representing oil and sebum release as sebaceous glands respond to treatment
  • Mild dryness lasting 1-2 days in some patients
  • Temporary mild acne flareup in the 1-2 weeks following treatment

Adverse Event Profile: The clinical trials documented no significant adverse events. Adverse effects that did occur were transient and self-resolving. No scarring, persistent hyperpigmentation, hypopigmentation, or other permanent side effects were observed.

No Systemic Side Effects: Unlike oral acne medications (isotretinoin, antibiotics, hormonal therapy), AviClear produces no systemic side effects. There is no photosensitivity, no interaction with medications, no impact on liver or kidney function, and no teratogenic risk.

Contraindications and Patient Selection

Absolute Contraindications:

  • Pregnancy
  • Current or recent treatment for skin cancer in the target area

Relative Contraindications and Precautions:

  • Current or recent isotretinoin (Accutane) use—typically counsel patients to wait 6-12 months after completing isotretinoin before AviClear treatment
  • Current anticoagulant therapy (warfarin, novel oral anticoagulants, aspirin)—increased bruising risk but not absolutely contraindicated
  • Active inflammatory skin condition other than acne in treatment area (severe rosacea, dermatitis)
  • History of malignant tumors in the target area
  • Significant coagulopathy or bleeding disorder
  • History of keloid formation or hypertrophic scarring
  • History of pigmentary disorders (vitiligo, significant post-inflammatory hyperpigmentation)
  • Active herpes simplex—postpone treatment until lesions have cleared
  • Open lesions or wounds in treatment area
  • Metal or electronic implants in the facial area
  • Flushing rosacea (non-transient rosacea) may be exacerbated by laser therapy

Areas Not Studied: The device has not been studied on the lips, upper and lower eyelids, and eyebrows. Clinicians should avoid treatment in these anatomically sensitive areas.

Combination Therapy and Integration with Medical Management

AviClear can be effectively combined with traditional acne therapies. Patients with moderate-to-severe inflammatory acne often benefit from continuing prescription acne medications (topical retinoids, benzoyl peroxide, oral antibiotics, or hormonal therapy) during and after AviClear treatment. The combination approach addresses multiple pathogenic factors and may improve overall outcomes.

Some practitioners utilize AviClear in patients with acne-prone skin but inadequate response to conventional therapies, or in those who cannot tolerate systemic medications. The lack of systemic side effects makes AviClear particularly attractive for patients who cannot use isotretinoin or other oral therapies due to contraindications or side effect concerns.

Comparison with Other Acne Energy-Based Devices

Previous energy-based acne treatments utilized different wavelengths and mechanisms. The 1726nm wavelength and selective sebaceous gland targeting distinguish AviClear from earlier laser and light-based systems. Alternative energy-based devices target bacterial components or general inflammatory pathways rather than specifically destroying sebaceous glands.

The 1726nm laser's selective photothermolysis of sebocytes represents a significant mechanistic advancement, offering durable long-term improvement by reducing sebaceous gland function rather than managing acne symptoms temporarily.

Long-Term Durability and Recurrence

Unlike medications that require ongoing use, AviClear provides durable long-term improvement. Rather than complete acne recurrence, clinical data demonstrates that future breakout episodes following AviClear are shorter in duration, less intense, and more infrequent compared to pre-treatment baseline. Approximately 92% of patients maintain significant acne clearance at one year post-treatment.

At two-year follow-up, approximately 88% of patients continue to demonstrate substantial acne control. Progressive improvement continues through the entire first year, with benefits stabilizing thereafter. The reduction in sebaceous gland function appears to be a durable effect, with the treated sebaceous glands maintaining permanently reduced capacity.

Some patients with severe, persistent acne may experience mild breakthrough breakouts requiring reinitiation of topical therapy, but these episodes are typically milder and more manageable than pre-treatment acne. Maintenance treatments may be considered for selected patients, though most benefit from the durability achieved with the initial three-treatment series.

Safety Profile and Diverse Populations

AviClear demonstrates excellent safety and equivalent efficacy across Fitzpatrick skin types II-VI. The selective sebaceous gland targeting and epidermal sparing result in a favorable adverse event profile independent of baseline skin phototype. Clinical trials documented no significant differences in efficacy or safety profiles across different ethnic populations.

The absence of epidermal damage and selective thermal targeting to sebaceous glands eliminates the risk of post-inflammatory hyperpigmentation or hypopigmentation that can occur with more aggressive resurfacing treatments. This makes AviClear particularly suitable for patients of color and those with higher risk of pigmentary complications.

Clinical Considerations and Patient Selection

Ideal candidates for AviClear include patients with moderate-to-severe inflammatory acne who seek long-term improvement without systemic medication side effects. Adolescents and young adults (after facial growth is complete) represent the primary population, though older patients with persistent acne also benefit.

Patients unable to tolerate oral medications due to contraindications (pregnancy planning, liver disease, drug interactions) represent excellent candidates. Women on hormonal therapy or seeking additional acne control benefit from AviClear's complementary mechanism of action. The three-treatment series fits well into typical patient treatment timelines, with minimal disruption to daily activities.

References

  • Goldberg DJ, et al. Selective photothermolysis with a novel 1726 nm laser beam: A safe and effective solution for acne vulgaris. J Cosmet Dermatol. 2023;22(4):1215-1222.
  • Cutera Inc. FDA Clears AviClear as a Long-Term Treatment for Mild to Severe Acne. News Release. 2022.
  • Study data: Safe and effective acne treatment across skin types with a 1726 nm sebum-selective laser: One year data from a prospective multicenter study. J Am Acad Dermatol. 2025;92(1):89-97.
  • Emerging lasers and light-based therapies in the management of acne: a review. J Clin Aesthet Dermatol. 2024;17(9):28-36.
  • 1726 nm Lasers for the Treatment of Acne Vulgaris. Skin Therapy Letter. 2024;29(3):6-9.
  • Sebum, science, and the 1726nm laser: Rethinking acne management in a post-antibiotic era. PMFA Journal. 2025;12(1):45-52.
  • Histological analysis of 1726nm laser treatment of sebaceous glands. Lasers Surg Med. 2024;56(2):156-163.
  • Long-term efficacy and safety of 1726nm laser treatment: 24-month follow-up data. Dermatol Surg. 2025;51(3):234-241.